AVI BioPharma Obtains $1,200,000 New Funding Round

  • Feed Type
  • Date
    7/28/2009
  • Company Name
    AVI BioPharma
  • Mailing Address
    One SW Columbia Portland, OR 97258
  • Company Description
    AVI BioPharma, Inc. (Nasdaq: AVII) is a biopharmaceutical company developing therapeutic products principally based on third generation NeuGene® antisense technology. Our principle products in development target life-threatening diseases, including cardiovascular and infectious diseases.
  • Website
    http://www.avibio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $1,200,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor
    Action Duchenne

By posting a comment, you agree to our terms and conditions.